Daniel J Stein

Daniel J. Stein, MD is a Professor and serves as Vice Chair for Education at the Medical College of Wisconsin (MCW). He is also the Director of the Inflammatory Bowel Disease (IBD) Program at Froedtert Hospital in Milwaukee, Wisconsin, where he oversees a comprehensive team dedicated to providing state-of-the-art care for patients with Crohn's disease, ulcerative colitis, and related conditions.

Dr. Stein's educational background includes:

• Doctor of Medicine from Creighton University School of Medicine (2003)
• Residency in Internal Medicine at the University of Arizona (2003-2006)
• Chief Residency in Internal Medicine at the University of Arizona (2006-2007)
• Fellowship in Gastroenterology and Hepatology at Medical College of Wisconsin (2007-2010)

Dr. Stein's research and clinical interests center on Inflammatory Bowel Disease, with particular focus on optimizing treatment strategies for Crohn's disease and ulcerative colitis. His work addresses practical clinical challenges including therapeutic drug monitoring, management of complex cases, and understanding the intersection of IBD with conditions like Clostridioides difficile infection. A native of Milwaukee, his dedication to IBD care was personally inspired when his mother was diagnosed with Crohn's disease during his high school years.

Analysis of Dr. Stein's recent publications (2016-2024) reveals a consistent focus on improving clinical outcomes through evidence-based approaches. His work frequently examines the relationship between IBD and C. difficile infection, therapeutic drug monitoring for biologics like infliximab and vedolizumab, and the long-term implications of IBD treatments. A notable trend in his research is the emphasis on personalized medicine approaches that consider individual patient factors beyond just disease activity.

As Director of the IBD Program, Dr. Stein leads a multidisciplinary team comprising physicians, physician assistants, nurses, nutritionists, and pharmacists. This team approach reflects his philosophy of treating 'the whole person' rather than just the disease, addressing each patient's unique challenges to help them achieve optimal quality of life despite their IBD diagnosis.